Terrence R Burke | Academic Influence

Why Is Terrence R Burke Influential?

Terrence R Burke's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. (1996) (1098)
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling (2006) (436)
Coumarin-based inhibitors of HIV integrase. (1997) (245)
Retroviral DNA integration: reaction pathway and critical intermediates (2006) (243)
Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. (1994) (241)
Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. (1994) (184)
Hydroxylated aromatic inhibitors of HIV-1 integrase. (1995) (178)
Grb2 signaling in cell motility and cancer (2008) (176)
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. (2002) (163)
Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. (1994) (155)
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. (1996) (146)
Protein–tyrosine phosphatases: Structure, mechanism, and inhibitor discovery (1998) (136)
Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of O-phosphotyrosine (1993) (127)
Chicoric acid analogues as HIV-1 integrase inhibitors. (1999) (127)
Azido-Containing Diketo Acid Derivatives Inhibit Human Immunodeficiency Virus Type 1 Integrase In Vivo and Influence the Frequency of Deletions at Two-Long-Terminal-Repeat-Circle Junctions (2004) (124)
Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. (1992) (122)
Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). (2003) (118)
Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. (1996) (113)
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 (2009) (110)
Protein Kinase C-ζ and Phosphoinositide-dependent Protein Kinase-1 Are Required for Insulin-induced Activation of ERK in Rat Adipocytes* (1999) (110)
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. (2000) (109)
Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. (1998) (108)
Structural Determinants for HIV-1 Integrase Inhibition by β-Diketo Acids* (2002) (105)
Irreversible ligands with high selectivity toward delta and mu opiate receptors. (1983) (100)
A general method for the preparation of benzylic α,α-difluorophosphonic acids; non-hydrolyzable mimemtics of phosphotyrosine (1992) (99)
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. (2006) (98)
Nonphosphorylated Peptide Ligands for the Grb2 Src Homology 2 Domain* (1997) (97)
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel (2011) (94)
Discovery of HIV-1 integrase inhibitors by pharmacophore searching. (1997) (94)
Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? (1995) (94)
Phosphotyrosyl mimetics in the development of signal transduction inhibitors. (2003) (94)
Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions* (2001) (89)
4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. (1996) (84)
Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. (1998) (80)
F(Pmp)-TAM, a Novel Competitive Inhibitor of the Binding of ZAP-70 to the T Cell Antigen Receptor, Blocks Early T Cell Signaling (*) (1995) (80)
Hydrazide-Containing Inhibitors of HIV-1 Integrase† (1997) (80)
Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. (1998) (80)
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants (2018) (79)
Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors (1997) (79)
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. (2015) (79)
Arylamide inhibitors of HIV-1 integrase. (1997) (79)
Integration Requires a Specific Interaction of the Donor DNA Terminal 5′-Cytosine with Glutamine 148 of the HIV-1 Integrase Flexible Loop* (2006) (78)
Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck. (1993) (77)
Metal-dependent inhibition of HIV-1 integrase. (2002) (76)
An engineered selenocysteine defines a unique class of antibody derivatives (2008) (76)
Purification of the opiate receptor of NG108-15 neuroblastoma-glioma hybrid cells. (1985) (75)
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. (2006) (74)
Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. (1999) (73)
Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. (2007) (69)
Identification of a M r 58 000 glycoprotein subunit of the opiate receptor (1982) (67)
Synthesis of 4-phosphono(difluoromethyl)-D,L-phenylalanine and N-boc and N-Fmoc derivatives suitably protected for solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues (1993) (66)
Enantioselective synthesis of N-boc and N-fmoc protected diethyl 4-phosphono(difluoromethyl)-L-phenylalanine; agents suitable for the solid-phase synthesis of peptides containing nonhydrolyzable analogues of O-phosphotyrosine (1994) (65)
Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors. (1995) (64)
Glucose Activates Mitogen-activated Protein Kinase (Extracellular Signal-regulated Kinase) through Proline-rich Tyrosine Kinase-2 and the Glut1 Glucose Transporter* (2000) (64)
Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction. (2010) (63)
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. (2012) (62)
Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. (2001) (60)
S‐[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals (1984) (60)
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design (2004) (59)
L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. (1995) (57)
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 (2009) (56)
Azido-Containing aryl β-Diketo acid HIV-1 integrase inhibitors (2003) (56)
Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. (2000) (56)
Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: Evidence for a two-site allosteric model (1984) (56)
Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases. (1995) (55)
Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for mu or delta opiate receptors. (1984) (55)
An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule (2009) (54)
Thermodynamic Study of Ligand Binding to Protein-tyrosine Phosphatase 1B and Its Substrate-trapping Mutants* (2000) (53)
An NMR strategy for fragment-based ligand screening utilizing a paramagnetic lanthanide probe (2011) (53)
Protein-Tyrosine Phosphatase Inhibition by a Peptide Containing the Phosphotyrosyl Mimetic, L-O-Malonyltyrosine (L-OMT) (1995) (52)
Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. (2009) (51)
Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. (2004) (48)
Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. (2004) (46)
High-resolution structure of the Yersinia pestis protein tyrosine phosphatase YopH in complex with a phosphotyrosyl mimetic-containing hexapeptide. (2003) (46)
Calcium ion dependent covalent modification of calmodulin with norchlorpromazine isothiocyanate. (1983) (46)
Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives (2002) (46)
ABSOLUTE CONFIGURATION OF GLYCEROL DERIVATIVES. 5. OXPRENOLOL ENANTIOMERS (1978) (46)
2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. (2008) (44)
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. (2002) (43)
15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits Transcriptional Activity of Estrogen Receptor-α via Covalent Modification of DNA-Binding Domain (2007) (43)
Effect of HIV integrase inhibitors on the RAG1/2 recombinase (2001) (43)
Enantioselective Synthesis of Nonphosphorus-Containing Phosphotyrosyl Mimetics and Their Use in the Preparation of Tyrosine Phosphatase Inhibitory Peptides (1998) (43)
Specific Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Integration in Cell Culture: Putative Inhibitors of HIV-1 Integrase (2001) (43)
Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays (2007) (42)
Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. (1997) (42)
A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells. (1999) (42)
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. (2007) (41)
Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality. (2009) (41)
Synthesis and application of N-Boc-L-2-amino-4-(diethylphosphono)-4,4-difluorobutanoic acid for solid-phase synthesis of nonhydrolyzable phosphoserine peptide analogues (1995) (40)
Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. (2013) (40)
Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. (2000) (40)
Phosphonate-containing inhibitors of tyrosine-specific protein kinases. (1991) (39)
Structural basis for strand-transfer inhibitor binding to HIV intasomes (2020) (39)
Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. (1998) (39)
Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase. (2011) (39)
Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase. (2001) (38)
Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for delta opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity. (1986) (38)
Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. (2004) (38)
Peptoid–Peptide Hybrid Ligands Targeting the Polo Box Domain of Polo‐Like Kinase 1 (2012) (37)
Cell protein cross-linking by erbstatin and related compounds. (1996) (35)
Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide, 4-(diisopropylamino)-2-(2-pyridyl)-2-phenylbutyramide. (1980) (35)
Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists. (2006) (35)
Bone marrow toxicity in vitro of chloramphenicol and its metabolites. (1982) (34)
Solid-phase synthesis of viscosin, a cyclic depsipeptide with antibacterial and antiviral properties (1989) (34)
Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems. (2003) (33)
Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants (2014) (33)
Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: Optimization of assay conditions (1985) (33)
Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. (1993) (33)
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines (2005) (33)
Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles. (2006) (33)
Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. (2009) (32)
MK-0536 Inhibits HIV-1 Integrases Resistant to Raltegravir (2011) (32)
Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking (1997) (31)
Novel aryl diketo-containing inhibitors of HIV-1 integrase (2002) (31)
Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates. (2012) (31)
Solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues with Nα-Fmoc-(O,O-di-t-butyl)phosphono-p-methylphenylalanine (1991) (31)
HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases (2016) (31)
Authentic HIV-1 integrase inhibitors. (2010) (31)
Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents (2006) (31)
Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. (2001) (30)
Pentafluorophenyl ester activation for the preparation of N,N′-diaroylhydrazines (1997) (30)
Use of a Heck reaction for the synthesis of a new alpha-azido phosphotyrosyl mimetic suitably protected for peptide synthesis. (2000) (30)
Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. (2004) (29)
Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: Evidence for delta←mu binding site interactions in vitro (1985) (29)
Preparation of 4-[Bis(tert-butoxy)phosphorylmethyl]-N-(fluoren-9-ylmethoxycarbonyl)-DL-phenylalanine. A Hydrolytically Stable Analogue of O-Phosphotyrosine Potentially Suitable for Peptide Synthesis (1991) (29)
Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors (2017) (29)
Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. (1998) (29)
HIV Integrase Inhibitors Block Replication of Alpha-, Beta-, and Gammaherpesviruses (2014) (29)
Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor. (2001) (28)
Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. (2005) (27)
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1 (2014) (27)
Synthesis of a difluorophosphonomethyl-containing phosphatase inhibitor designed from the X-ray structure of a PTP1B-bound ligand (1996) (26)
Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors. (1999) (26)
Deprotection and cleavage methods for protected peptide resins containing 4-[(diethylphosphono)difluoromethyl]-D,L-phenylalanine residues (1993) (26)
Chemically Programmed Bispecific Antibodies in Diabody Format * (2016) (26)
Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. (1997) (26)
Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic. (2006) (26)
Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. (2003) (25)
SAR by Oxime‐Containing Peptide Libraries: Application to Tsg101 Ligand Optimization (2008) (25)
QSAR of conformationally flexible molecules: Comparative Molecular Field Analysis of protein-tyrosine kinase inhibitors (1992) (25)
Probes for narcotic receptor mediated phenomena. XI: Synthesis of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinans (foxy and cyclofoxy) as models of opioid ligands suitable for positron emission transaxial tomography (1985) (25)
Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. (1985) (25)
Synthesis of a 5-methylindolyl-containing macrocycle that displays ultrapotent Grb2 SH2 domain-binding affinity. (2004) (25)
F2(Pmp)2-TAM zeta 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling. (1995) (24)
Bicyclic Hydroxy‐1H‐pyrrolopyridine‐trione Containing HIV‐1 Integrase Inhibitors (2012) (24)
Mechanism of defluorination of enflurane. Identification of an organic metabolite in rat and man. (1981) (24)
The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution (1987) (24)
Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides. (2009) (23)
Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration. (2003) (23)
Development of Efficient Two-Step Deprotection Methodology for Dimethyl-Protected Phosphoamino Acid-Containing Peptide Resins and Its Application to the Practical Synthesis of Phosphopeptides (1995) (23)
Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain. (1999) (23)
Phencyclidine-induced catalepsy in pigeons: specificity and stereoselectivity. (1984) (23)
Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity. (1983) (22)
Mono‐anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo‐box domain‐binding affinities and enhanced antiproliferative effects in hela cells (2014) (22)
Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase (2018) (22)
Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. (2005) (22)
Stable and Potent Selenomab-Drug Conjugates. (2017) (22)
Chemically Programmed Bispecific Antibodies That Recruit and Activate T Cells* (2012) (21)
N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding. (2001) (21)
A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. (2003) (21)
Probes for narcotic receptor mediated phenomena. 9. Synthesis of (+/-)-(3 alpha,6a alpha,11a beta)-1,3,4,5,6,11a-hexahydro-2-methyl-2H-3,6a- methanobenzofuro[2,3-c]azocin-10-ol, an oxide-bridged 5-(m-hydroxyphenyl)morphan. (1986) (21)
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. (2011) (21)
Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors. (1993) (21)
Hydrazide-containing inhibitors of HIV-1 integrase. (1997) (21)
Biotinylated biphenyl ketone-containing 2,4-dioxobutanoic acids designed as HIV-1 integrase photoaffinity ligands. (2006) (21)
Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). (2012) (21)
Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor (2008) (20)
Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. (2019) (20)
Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase. (2003) (20)
Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif. (2001) (20)
Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic. (2005) (20)
Preparation of aryl isothiocyanates via protected phenylthiocarbamates and application to the synthesis of caffeic acid (4-isothiocyanato)phenyl ester. (2000) (19)
Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues. (2011) (19)
Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. (2013) (19)
Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides. (2008) (19)
L-O-(2-malonyl)tyrosine (L-OMT) a new phosphotyrosyl mimic suitably protected for solid-phase synthesis of signal transduction inhibitory peptides (1995) (19)
Probes for narcotic receptor mediated phenomena. 4. Synthesis of (.+-.)-2,3,4,5,6,6a-hexahydro-3-methyl-8-hydroxy-1H-4,11b-methanobenzofuro[3,2-d]azocine, an oxide-bridged 5-(m-hydroxyphenyl)morphan (1984) (19)
Ring‐Closing Metathesis of C‐Terminal Allylglycine Residues with an N‐Terminal β‐Vinyl‐Substituted Phosphotyrosyl Mimetic as an Approach to Novel Grb2 SH2 Domain‐Binding Macrocycles (2005) (18)
Oxime-based linker libraries as a general approach for the rapid generation and screening of multidentate inhibitors (2012) (18)
Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes. (2004) (18)
Protein‐tyrosine kinases: Potential targets for anticancer drug development (1994) (18)
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors. (2012) (18)
HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants (2018) (18)
Synthesis of phosphonomethyl-phenylalanine and phosphotyrosine containing cyclic peptides as inhibitors of protein tyrosine kinase/SH2 interactions (1994) (18)
A rapid oxime linker-based library approach to identification of bivalent inhibitors of the Yersinia pestis protein-tyrosine phosphatase, YopH. (2010) (18)
Synthesis of tripeptides as potent Yersinia protein tyrosine phosphatase inhibitors. (2005) (17)
Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT). (1998) (17)
Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics. (2005) (17)
Evidence that the delta-selective alkylating agent, FIT, alters the mu-noncompetitive opiate delta binding site (1985) (17)
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents (2017) (17)
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs (2021) (16)
The Stereoselective Disposition of Disopyramide in the Dog (1980) (16)
Phosphatase‐Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo‐Box Domain of Polo‐like Kinase 1 (2017) (16)
Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme–DNA interactions in the active site (2016) (16)
Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. (2002) (16)
Morphine tolerance increases mu-noncompetitive delta binding sites. (1986) (15)
Facile Syntheses of (2R,3R)-(−)- and (2S,3S)-(+)-Chicoric Acids (1998) (15)
Samarium iodide-mediated Reformatsky reactions for the stereoselective preparation of β-hydroxy-γ-amino acids: synthesis of isostatine and dolaisoleucine. (2012) (15)
Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding. (1994) (15)
Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. (2019) (15)
Chemically programmable and switchable CAR-T therapy. (2020) (15)
Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. (2005) (15)
Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. (2016) (15)
15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. (2007) (14)
A Concise Synthesis of the Differentiating Antibiotic l-Azatyrosine (1995) (14)
Solvent Systems for the Countercurrent Chromatography of Hydrophobic Neuropeptide Analogs and Hydrophilic Protein Fragments (1988) (14)
HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants (2020) (14)
Synthesis of Fmoc-protected 4-carboxydifluoromethyl-L-phenylalanine: A phosphotyrosyl mimetic of potential use for signal transduction studies (1999) (14)
Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: Evidence for a two-site allosteric model (1984) (14)
CD45 protein-tyrosine phosphatase inhibitor development. (2003) (13)
Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. (2006) (13)
Synthesis of α,α-disubstituted 4-phosphonophenylalanine analogues as conformationally-constrained phosphotyrosyl mimetics (2004) (13)
Probes for narcotic receptor mediated phenomena. 6. Synthesis of (.+-.)-(1.alpha.,4a.alpha.,9a.beta.)-1,3,4,9a-tetrahydro-2-methyl-2H-1,4a-propanobenzofuro[2,3-c]pyridin-8-ol, an oxide-bridged 5-(3-hydroxyphenyl)morphan (1984) (13)
The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. (1995) (13)
Oxime‐Based Click Chemistry in the Development of 3‐Isoxazolecarboxylic Acid Containing Inhibitors of Yersinia pestis Protein Tyrosine Phosphatase, YopH (2011) (13)
Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. (2017) (13)
Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. (2005) (13)
Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands. (2011) (12)
Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. (2009) (12)
Isothiazolidinone (IZD) as a phosphoryl mimetic in inhibitors of the Yersinia pestis protein tyrosine phosphatase YopH. (2011) (12)
Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. (2014) (12)
Synthesis of N-Fmoc 3-(4-(di-(tert-butyl)phosphonomethyl)-phenyl)pipecolic acid as a conformationally constrained phosphotyrosyl mimetic suitably protected for peptide synthesis (2002) (12)
Neighbor‐directed histidine N (τ)–alkylation: A route to imidazolium‐containing phosphopeptide macrocycles (2015) (12)
Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck. (1991) (11)
Synthesis of a New Tyrosine Analogue Having χ1 and χ2 Angles Constrained to Values Observed for an SH2 Domain-Bound Phosphotyrosyl Residue (1997) (11)
DESIGN AND SYNTHESIS OF PHOTOACTIVATABLE COUMARIN-CONTAINING HIV-1 INTEGRASE INHIBITORS (1997) (11)
Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist. (2008) (11)
Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: A highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding (1984) (11)
PROBES FOR NARCOTIC RECEPTOR MEDIATED PHENOMENA. 7. SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF IRREVERSIBLE LIGANDS SPECIFIC FOR μ OR Δ OPIATE RECEPTORS (1985) (10)
Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine (1983) (10)
Application of ring‐closing metathesis to Grb2 SH3 domain‐binding peptides (2011) (10)
Effect of DNA Modifications on DNA Processing by HIV-1 Integrase and Inhibitor Binding (2006) (10)
Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids. (2008) (10)
Yersinia pestis and approaches to targeting its outer protein H protein-tyrosine phosphatase (YopH). (2012) (10)
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. (2008) (10)
Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation. (2011) (10)
Enantioselective synthesis of N(alpha)-Fmoc protected (2S,3R)-3-phenylpipecolic acid. A constrained phenylalanine analogue suitably protected for solid-phase peptide synthesis. (2002) (9)
Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. (2018) (9)
Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions. (2020) (9)
Synthesis of a phosphotyrosyl analogue having χ1, χ2 and φ angles constrained to values observed for an SH2 domain-bound phosphotyrosyl residue (2003) (9)
Increased affinity of dimeric enkephalins is not dependent on receptor density (1985) (9)
HIV-1 Integrase and Virus and Cell DNAs: Complex Formation and Perturbation by Inhibitors of Integration (2010) (9)
Investigation of the mechanism of defluorination of enflurane in rat liver microsomes with specifically deuterated derivatives. (1980) (9)
A new synthetic method for the synthesis of hydroxylated isoquinolines : preparation of methyl 6,7- and 7,8-dihydroxy-isoquinoline-3-carboxylates, potential protein-tyrosine kinase inhibitors (1992) (9)
Development of antiproliferative phenylmaleimides that activate the unfolded protein response. (2010) (9)
Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. (2009) (8)
Norleucine as a replacement for methionine in phosphatase-resistant linear and cyclic peptides which bind to p85 SH2 domains (1994) (8)
Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. (2007) (8)
Preparation of l-Nα-Fmoc-4-[di-(tert-butyl)phosphonomethyl]phenylalanine from l-tyrosine (1999) (8)
Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids. (2009) (8)
Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites† (2021) (8)
Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists. (2010) (8)
Design and synthesis of 4-(alpha-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides. (2005) (8)
Structural examination of ring-closing metathesis-derived 15-member macrocycles as Grb2 SH2 domain-binding tetrapeptide mimetics. (2007) (8)
HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants (2021) (7)
Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors (1992) (7)
Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides. (2007) (7)
Synthesis of the First α‐Fluoro‐Phosphotyrosyl Mimetic (2004) (7)
Pathways of propranolol metabolism. Use of the stable isotope twin-ion GC-MS technique to examine the conversion of propranolol to propranolol-diol by 9000g rat liver supernatant. (1978) (7)
Preparation of Nα-Boc 4-O-Diethylphospho-L-azatyrosine, a Regent Potentially Useful for the Synthesis of Signal Transduction Related Peptides (1996) (7)
Aromatic hydroxylation of beta-adrenergic antagonists. Formation of 4'- and 5'-hydroxy-1-(isopropylamino)-3-[2'-allyloxy)phenoxy]-2-propanol from oxprenolol. (1979) (7)
Comparison of metal-dependent catalysis by HIV-1 and ASV integrase proteins using a new and rapid, moderate throughput assay for joining activity in solution (2009) (7)
Phosphotyrosyl Mimetics in the Development of Signal Transduction Inhibitors (2003) (7)
Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro (1984) (6)
Metabolism of beta-adrenergic antagonists. Evidence for an arene oxide-NIH shift pathway in the aromatic hydroxylation of oxprenolol. (1979) (6)
Probes for narcotic receptor mediated phenomena 8. Tritiation of irreversible mu or delta specific opioid receptor affinity ligands to high specific activity (1984) (6)
6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors. (2015) (6)
Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides. (2003) (6)
Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form (2013) (6)
Utilization of a Common Pathway for the Synthesis of High Affinity Macrocyclic Grb2 SH2 Domain‐Binding Peptide Mimetics That Differ in the Configuration at One Ring Junction (2005) (6)
Synthesis, configuration, and evaluation of two conformationally restrained analogues of phencyclidine. (1988) (6)
Carbon-13 nuclear magnetic resonance studies of spironolactone and several related steroids (1980) (6)
Probes for narcotic receptor mediated phenomena 3. Oxide bridged 5-phenylmorphans. (1984) (5)
Synthesis of 4'- and 5'-hydroxyoxprenolol:pharmacologically active ring-hydroxylated metabolites of oxprenolol. (1979) (5)
Design of a cyclic bombesin analog (1990) (5)
Procaine isothiocyanate: An irreversible inhibitor of the specific binding of [3H]batrachotoxinin-A benzoate to sodium channels (1990) (5)
A new pathway for the oxidative metabolism of chloramphenicol by rat liver microsomes. (1982) (5)
Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine. (1995) (5)
Acylsulfonamide‐Containing PTP1B Inhibitors Designed to Mimic an Enzyme‐Bound Water of Hydration. (2004) (5)
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist (2013) (5)
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo. (1983) (5)
ENANTIOSELECTIVE SYNTHESIS OF N-Boc AND N-Fmoc PROTECTED DIETHYL 4-PHOSPHONO(DIFLUOROMETHYL)-L-PHENYLALANINE (F2Pmp) (1996) (4)
Phosphotyrosyl-Based Motifs in the Structure-Based Design of Protein Tyrosine Kinase-Dependent Signal Transduction Inhibitors (1997) (4)
Probes for Narcotic Receptor Mediated Phenomena. Part 9. Synthesis of (±)-(3α,6aα,11aβ)-1,3,4,5,6,11a-Hexahydro-2-methyl-2H-3,6a-methanobenzofuro[2,3-c]azocin-10-ol, an Oxide-Bridged 5-(m-Hydroxyphenyl)morphan. (1986) (4)
A DIRECT APPROACH TOWARD THE SYNTHESIS OF ANALOGS OF ERBSTATIN (1991) (4)
Actions of 'irreversible' delta opiate receptor agonists on the mouse vas deferens (1985) (4)
LARGE SCALE PREPARATION OF CELL PERMEABLE, NON-PHOSPHATE-CONTAINING GRB2 SH2 DOMAIN INHIBITORS (2000) (4)
Synthesis of deuterated and tritiated derivatives of enflurane (1981) (4)
Reductive dechlorination of chloramphenicol by rat liver microsomes. (1983) (4)
Activity of Estrogen Receptor-A via Covalent Modification of DNA-Binding Domain (2007) (4)
Biomolecular Interactions of Small‐molecule Inhibitors Affecting the YopH Protein Tyrosine Phosphatase (2013) (4)
Preparation of Orthogonally-Protected 3-Methoxy-4-Phosphonomethyl-LPhenylalanine,a New Reagent for the Synthesis of Phosphotyrosyl Mimetic-Containing Peptides (2007) (4)
Aromatic hydroxylation of beta-adrenergic antagonists. 4- and 5-hydroxylation of 1-(isopropylamino)-3-[2-(allyloxy)phenoxy]-2-propanol (oxprenolol). (1978) (4)
Preparative reversed-phase high-performance liquid chromatography in the synthesis of viscosin, a cyclic depsipeptide. (1989) (4)
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1 (2019) (4)
Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs. (2013) (4)
Azido-Containing Aryl β-Diketo Acid HIV-1 Integrase Inhibitors. (2003) (4)
Mitsunobu mischief: neighbor-directed histidine N(τ)-alkylation provides access to peptides containing selectively functionalized imidazolium heterocycles. (2015) (4)
Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase. (1996) (4)
RESOLUTION, ABSOLUTE CONFIGURATION, AND ANTIARRHYTHMIC PROPERTIES OF THE ENANTIOMERS OF DISOPYRAMIDE, 4-(DIISOPROPYLAMINO)-2-(2-PYRIDYL)-2-PHENYLBUTYRAMIDE (1981) (3)
Reversed-phase preparative chromatography of [D-Ala1]-peptide T amide. (1988) (3)
Practical synthesis of phosphopeptides using dimethyl-protected phosphoamino acid derivatives (1995) (3)
PROBES FOR NARCOTIC RECEPTOR MEDIATED PHENOMENA. 6. SYNTHESIS OF (.+-.)-(1α,4Aα,9Aβ)-1,3,4,9A-TETRAHYDRO-2-METHYL-2H-1,4A-PROPA# NOBENZOFURO(2,3-C)PYRIDIN-8-OL, AN OXIDE-BRIDGED 5-(3-HYDROXYPHENYL)MORPHAN (1984) (3)
Design and Synthesis of Fmoc‐Thr[PO(OH)(OPOM)] for the Preparation of Peptide Prodrugs Containing Phosphothreonine in Fully Protected Form (2014) (3)
INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay (2021) (3)
Developing and evaluating inhibitors against the RNase H active site of HIV-1 RT. (2018) (3)
Counter-current chromatographic purification of [D-Ala]peptide T amide. (1987) (3)
Elucidation of New Binding Interactions with the Human Tsg101 Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands (2011) (3)
2,5-Dimethyl-2′-hydroxy-9α- and 9β-(3-Methylbutyl)-6,7-benzomorphans and N-Substituted Compounds in the 9α-(3-Methylbutyl) Series: Chemistry, Pharmacology, and Biochemistry (1987) (3)
Synthesis and structure-activity studies of SH2 binding peptides containing hydrolytically stable analogs of O -phosphotyrosine (1994) (3)
Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors (2019) (3)
[33]Synthesis and properties of CAPP1-calmodulin (1987) (3)
Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs. (2014) (3)
Design and synthesis of a beta-amino phosphotyrosyl mimetic suitably protected for peptide synthesis. (2002) (2)
Synthesis of a Difluorophosphonomethyl-Containing Phosphatase Inhibitor Designed from the X-Ray Structure of a PTP1B-Bound Ligand. (1996) (2)
A one-step synthesis of Nα-Fmoc-4-O-[O′,O″-di-tert-butyl-2-(2-fluoromalonyl)]-l-tyrosine from commercially available starting material (2004) (2)
Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds. (2019) (2)
Structural influences of styryl-based inhibitors on epidermal growth factor receptor and p56lck tyrosine-specific protein kinases. (1991) (2)
Phospho-Azatyrosine, a less effective protein-tyrosine phosphatase substrate than phosphotyrosine. (2001) (2)
Stereoselective Preparation of l-4-(2′-Malonyl)phenylalanine Suitably Protected for Fmoc-Based Synthesis of Potent Signal Transduction Inhibitory Ligands (2000) (2)
Antiviral resistance to diketo acids is associated with the mutations T66I, L74M and S230R in the HIV-1 integrase gene (2002) (2)
Preparation of Nα‐Boc 4‐O‐Diethylphospho‐L‐azatyrosine, a Reagent Potentially Useful for the Synthesis of Signal Transduction Related Peptides. (1996) (2)
Examination of the possible mediation of antineoplastic effects of opiates through the inhibition of tyrosine-specific protein kinases. (1991) (2)
Preparation of 4‐(Bis(tert‐butoxy)phosphorylmethyl)‐N‐(fluoren‐9‐ ylmethoxycarbonyl) ‐DL‐phenylalanine. A Hydrolytically Stable Analogue of O‐Phosphotyrosine Potentially Suitable for Peptide Synthesis. (1992) (2)
Harnessing the Fc m Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia (2014) (2)
HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence (2018) (2)
A General Method for the Preparation of Benzylic α,α- Difluorophosphonic Acids. Non-Hydrolyzable Mimetics of Phosphotyrosine. (1993) (2)
Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides. (2005) (1)
Use of a Heck Reaction for the Synthesis of a New α-Azido Phosphotyrosyl Mimetic Suitably Protected for Peptide Synthesis. (2001) (1)
Identification of lymphoid cells in cultured of murine leukocytes and thymus. (1975) (1)
SYNTHESIS OF 4′- AND 5′-HYDROXYOXPRENOLOL: PHARMACOLOGICALLY ACTIVE RING-HYDROXYLATED METABOLITES OF OXPRENOLOL (1980) (1)
PROBES FOR NARCOTIC RECEPTOR MEDIATED PHENOMENA. 4. SYNTHESIS OF (.+-.)-2,3,4,5,6,6A-HEXAHYDRO-3-METHYL-8-HYDROXY-1H-4,11B-METHANOBENZOFURO(3,2-# D)AZOCINE, AN OXIDE-BRIDGED 5-(M-HYDROXYPHENYL)MORPHAN (1984) (1)
HIV Viral Protein R (Vpr)-Derived Peptides Designed as HIV-1 Integrase Photoaffinity Ligands (2013) (1)
Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain – binding peptide macrocycles (2021) (1)
AROMATIC HYDROXYLATION OF β-ADRENERGIC ANTAGONISTS. FORMATION OF 4′- AND 5′-HYDROXY-1-(ISOPROPYLAMINO)-3-(2′-(ALLYLOXY)PHENOXY)-2-PROPANOL FROM OXPRENOLOL (1980) (1)
4 Viral entry as the primary target of anti-HIV activity of chicoric acid and its tetra-acetyl esters (2000) (1)
Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures (2021) (1)
PREPARATION OF PHOSPHO-L-AZATYROSINE SUITABLY PROTECTED FOR THE SYNTHESIS OF SIGNAL TRANSDUCTION RELATED PEPTIDES. A CORRECTION (1998) (1)
Enantioselective Synthesis of N-Boc and N-Fmoc Protected Diethyl 4- Phosphono(difluoromethyl)-L-Phenylalanine (IV) and (V): Agents Suitable for the Solid-Phase Synthesis of Peptides Containing Nonhydrolyzable Analogues of O-Phosphotyrosine. (1994) (1)
Enantioselective Synthesis of (S)‐3‐Carboxy‐4‐((carboxy)difluoromethyl)phenylalanine in Protected Form and Its Incorporation into a PTP‐1B‐Directed Tripeptide (2004) (1)
Enantioselective Synthesis of Nonphosphorus‐Containing Phosphotyrosyl Mimetics and Their Use in the Preparation of Tyrosine Phosphatase Inhibitory Peptides. (1998) (1)
A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. (2020) (1)
Synthesis and structure activity studies of phosphatase resistant SH2 domain inhibiting peptides: D-amino acid effects (1995) (1)
High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design. (2018) (1)
NMR structure of growth factor receptor binding protein SH2 domain complexed with the inhibitor (2005) (0)
Preparation of Fluoro- and Hydroxy-4-(phosphonomethyl)-D,L- phenylalanine (I) Suitably Protected for Solid-Phase Synthesis of Peptides Containing Hydrolytically Stable Analogues of O- Phosphotyrosine. (2010) (0)
Polo-like kinase 1 Polo box domain in complex with a C6H5(CH2)8-derivatized peptide inhibitor (2011) (0)
Novel mutations in HIV-1 integrase associated with resistance to diketo acids (2001) (0)
Facile Syntheses of (2R,3R)‐(‐)‐ and (2S,3S)‐(+)‐Chicoric Acids. (1998) (0)
2,5-Dimethyl-2'-hydroxy-9 alpha- and 9 beta-(3-methylbutyl)-6,7-benzomorphans and N-substituted compounds in the 9 alpha-(3-methylbutyl) series: chemistry, pharmacology, and biochemistry. (1987) (0)
Probes for Narcotic Receptor Mediated Phenomena. Part 12. cis-(+)-3-Methylfentanyl Isothiocyanate, a Potent Site-Directed Acylating Agent for δ Opioid Receptors. (1986) (0)
Oxime-based Post Solid-phase Peptide Diversification: Identification of High Affinity Polo-like Kinase 1 (Plk1) Polo-box Domain Binding Peptides (2012) (0)
Design and Synthesis of Photoactivatable Coumarin-Containing HIV-1 Integrase Inhibitors. (1998) (0)
Design and Synthesis of Photoactivatable Aryl Diketo Acid‐Containing HIV‐1 Integrase Inhibitors (I) as Potential Affinity Probes. (2004) (0)
Deprotection and Cleavage Methods for Protected Peptide Resins Containing 4‐((Diethylphosphono)difluoromethyl)‐D,L‐phenylalanine Residues. (1994) (0)
Corrigendum: Phosphatase‐Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo‐Box Domain of Polo‐like Kinase 1 (2017) (0)
Plk-1 polo-box domain in complex with histidine N(tau)-cyclized Macrocycle 5b. (2018) (0)
Inhibition of HIV-1 replication and integrase activity by a series of diketo derivatives (2001) (0)
INHIBITION DU FACTEUR DE TRANSCRIPTION NUCLEAIRE NF-λB PAR L'ESTER PHENETHYLIQUE D'ACIDE CAFEIQUE, LES DERIVES DE CET ESTER, LA CAPSAICINE (8-METHYL-N-VANILLYLE-6-NONEAMIDE) ET LA RESINIFERATOXINE (1997) (0)
Structure of Tdp1 catalytic domain in complex with inhibitor XZ633p (2021) (0)
15-Deoxy-#-Prostaglandin J2 Inhibits Transcriptional Activity of Estrogen Receptor-A via Covalent Modification of DNA-Binding Domain (2007) (0)
Meet Our Editorial Board Member (2019) (0)
Enantioselective Synthesis of Metathesis-Derived Ureapeptoid Macrocycles (2004) (0)
Phosphatase-resistant SH2 domain inhibitors (1994) (0)
Peptides Containing Mono-anionic Phosphothreonine Esters That Exhibit High Plk1 Polo-box Domain-binding Affinities and Potent Antiproliferative Effects in HeLa Cells (2013) (0)
Selection of antiviral resistance against diketo derivatives, authentic inhibitors of HIV-1 integration (2001) (0)
Synthesis of the First α-Fluoro-phosphotyrosyl Mimetic. (2005) (0)
Aromatic hydroxylation of oxprenolol. Quantitation and stereoselectivity in the formation of 4'- and 5-hydroxyoxprenolol in vivo in the rat. (1980) (0)
Preparation of Orthogonally-Protected 3-Methoxy-4-phosphonomethyl-L-phenylalanine, a New Reagent for the Synthesis of Phosphotyrosyl Mimetic-Containing Peptides. (2008) (0)
Cover Picture: Peptoid–Peptide Hybrid Ligands Targeting the Polo Box Domain of Polo‐Like Kinase 1 (ChemBioChem 9/2012) (2012) (0)
Erratum to “Design and Synthesis of a β-Amino Phosphotyrosyl Mimetic Suitably Protected for Peptide Synthesis”[Bioorg. Med. Chem. Lett. 12 (2002) 3399]☆ (2003) (0)
Large Scale Preparation of Cell Permeable, Non-Phosphate-Containing Grb2 SH2 Domain Inhibitors. (2000) (0)
Synthesis and Biological Activity of Cholecystokinin Antagonists (1993) (0)
High affinity nonphosphorylated cyclic peptide inhibitors of Grb2-SH2/growth factor receptor interactions (2002) (0)
A New Synthetic Method for the Synthesis of Hydroxylated Isoquinolines: Preparation of Methyl 6,7‐ and 7,8‐Dihydroxyisoquinoline‐3‐ carboxylates, Potential Protein‐Tyrosine Kinase Inhibitors. (1992) (0)
Application of Post Solid-Phase Oxime Ligation to Fine-Tune Peptide–Protein Interactions (2020) (0)
Molecular mechanism of salicylhydrazide class of compounds (2007) (0)
Design and Synthesis of Phosphonodifluoromethyl Phenylalanine (F2Pmp): A Useful Phosphotyrosyl Mimetic (2007) (0)
SYNTHESIS AND PHARMACOLOGICAL CHARACTERIZATION OF (.+-.)-5,9α-DIMETHYL-2-(2-(4-FLUOROPHENYL)ETHYL)-2′-HYDROXY-6,7-BENZOMORP# HAN (FLUOROPHEN), A LIGAND SUITABLE FOR VISUALIZATION OF OPIATE RECEPTORS IN VIVO (1984) (0)
Structure-based design of small molecule protein-tyrosine phosphatase inhibitors (2002) (0)
High Affinity Grb2 SH2 Domain-Binding Macrocycles Derived from Ring-Closing Methathesis of Alkenylglyicne Residues with β-Vinyl Phosphotyrosyl Mimetics (2006) (0)
Crystal Structure of the Yersinia Pestis Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide (2003) (0)
Abstract A163: Development of Grb2 SH3 domain antagonists (2009) (0)
Pentafluorophenyl Ester Activation for the Preparation of N,N′- Diaroylhydrazines. (1997) (0)
METABOLISM OF β-ADRENERGIC ANTAGONISTS. EVIDENCE FOR AN ARENE OXIDE-NIH SHIFT PATHWAY IN THE AROMATIC HYDROXYLATION OF OXPRENOLOL (1980) (0)
Synthesis of 4-Phosphono(difluoromethyl)-D,L-phenylalanine and N-Boc and F-Fmoc Derivatives Suitably Protected for Solid-Phase Synthesis of Nonhydrolyzable Phosphotyrosyl Peptide Analogues. (1993) (0)
A Direct Approach Toward the Synthesis of Analogs of Erbstatin. (2010) (0)
Oxide-bridged 5-phenylmorphans as probes for narcotic receptor mediated phenomena. (1990) (0)
Synthesis and properties of CAPP1-calmodulin. (1987) (0)
Application of Protein Covalent Modification to Studying Structure and Function of HIV‐1 Integrase and Its Inhibitors (2011) (0)
Meet Our Editorial Board Member (2020) (0)
PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 3B (2015) (0)
Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate (2013) (0)
Inhibition of cell motility and angiogenesis with GRB2 SH2-domain-inhibitors (2000) (0)
Author ' s personal copy Development of antiproliferative phenylmaleimides that activate the unfolded protein response (2010) (0)
Fcμ-Receptor (FcμR; TOSO/FAIM3) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells (2011) (0)
Running Title: Thermodynamics of Ligand Binding to PTP1B (2000) (0)
Local Conformational Constraint in the Design of a Grb2 SH2 Domain Inhibitor (2001) (0)
Crystal structure of Tdp1 catalytic domain in complex with compound XZ519 (2019) (0)
Identification of lead compounds for inhibitor design against tyrosyl DNA phosphodiesterase I by crystallographic fragment screening (2017) (0)
2,5-Dimethyl-2′-hydroxy-9α- and -9β-(3-methylbutyl)-6,7-benzomorphans and N-Substituted Compounds in the 9α-(3-Methylbutyl) Series: Chemistry, Pharmacology, and Biochemistry. (1988) (0)
Synthesis and Application of N‐Boc‐L‐2‐amino‐4‐(diethylphosphono)‐4,4‐ difluorobutanoic Acid (VI) for Solid‐Phase Synthesis of Nonhydrolyzable Phosphoserine Peptide Analogues. (1995) (0)
Crystal structure of Yersinia pestis YopH in complex with an aminooxy- containing platform compound for inhibitor design (2011) (0)
Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1 (2022) (0)
Alkyl-substituted gamma-butyrolactones inhibit [35S]TBPS binding to a GABA linked chloride ionophore. (1984) (0)
Meet Our Editorial Board Member (2020) (0)
Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1 (2022) (0)
Structure of Tdp1 catalytic domain in complex with inhibitor XZ635p (0)
Analogs of the cyclic depsipeptide antibiotic viscosin (1990) (0)
Mechanisms of HIV-1 Integrase Resistance to Dolutegravir and Potent Inhibition of Drug Resistant Variants (2022) (0)
Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment benzene-1,2,4-tricarboxylic acid from single soak (2019) (0)
Design and synthesis of a new tyrosine analog having χ 1 and χ 2 angles constrained to values observed for an SH2 domain-bound phosphotyrosyl residue (2002) (0)
HUMAN PTP1B CATALYTIC DOMAIN COMPLEXED WITH TPI (1999) (0)
Structure of Tdp1 catalytic domain in complex with inhibitor XZ632p (2021) (0)
AROMATIC HYDROXYLATION OF β-ADRENERGIC ANTAGONISTS. 4- AND 5-HYDROXYLATION OF 1-(ISOPROPYLAMINO)-3-(2-(ALLYLOXY)PHENOXY)-2-PROPANOL (OXPRENOLOL) (1979) (0)
Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form (2013) (0)
Design and Synthesis of a β‐Amino Phosphotyrosyl Mimetic Suitably Protected for Peptide Synthesis. (2003) (0)
Synthesis and Use of C-terminally Biotinylated Peptidomimetics with High Grb2 SH2 Domain-binding Affinity (2006) (0)
The structure of protein tyrosine phosphatase-1B complexed to a high affinity inhibitor (1996) (0)
Novel insight into the mechanism of action and selectivity of the Grb2 Src homology 2 domain binding antagonist C90. (2007) (0)
Crystal structure of YopH in complex with 3-(1,1-dioxido-3- oxoisothiazolidin-5-yl)benzaldeyde (2011) (0)
Terrence Inhibitors of HIV-1 Integrase Integration in Cell Culture : Putative Immunodeficiency Virus Type 1 ( HIV-1 ) Specific Inhibition of Human (2001) (0)
Purification of the opiate receptor of NG 108-15 neuroblastoma-glioma hybrid cells ( affinity labeling / 6 opiate receptor / glycoprotein ) (0)
Structure of Tdp1 catalytic domain in complex with inhibitor XZ634p (2021) (0)
Cyclic peptide inhibitor of human PTP1B (1999) (0)
Induction of theta-positive murine lymphocytes by a thymic extract. (1976) (0)
Analogues acetyles et correspondants d'acide chicorique en tant qu'inhibiteurs de l'integrase du vih (2000) (0)
A One‐Step Synthesis of Nα‐Fmoc‐4‐O‐ [O′,O′′‐di‐tert‐butyl‐2‐(2‐fluoromalonyl)]‐L‐tyrosine from Commercially Available Starting Material. (2005) (0)
Novel IgM-derived antibody-drug conjugate selectively kills chronic lymphocytic leukemia cells through binding of Fcμ-receptor leading to rapid internalization and intracellular cytotoxic payload delivery (VAC3P.953) (2014) (0)
Incorporation of Phosphotyrosyl Mimetic 4‐(Phosphonodifluoromethyl)phenyl Alanine (F2Pmp) into Signal Transduction‐Directed Peptides (2006) (0)
Publisher Correction: Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures (2021) (0)
Application of Phenylphosphate Mimetics to the Design and Synthesis of Olefin Metathesis-Derived Grb2 SH2 Domain-Binding Macrocycles (2006) (0)

This paper list is powered by the following services:

Other Resources About Terrence R Burke

ccr.cancer.gov

What Schools Are Affiliated With Terrence R Burke?

Terrence R Burke is affiliated with the following schools:

Saint Martin's University
Ohio State University
Albert Einstein College of Medicine
Georgetown University
University of Washington